OncoMatch/Clinical Trials/NCT07002216
BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma
Is NCT07002216 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for hodgkin lymphoma.
Treatment: Brentuximab Vedotin · Etoposide · Cyclophosphamide · Doxorubicin · Dacarbazine · Dexamethasone — The purpose of this study is to further assess the efficacy and tolerability of a regimen of Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone (BrECADD) in patients with Stage 2 B-IV Hodgkin Lymphoma (HL) with an exploratory objective to assess the clinical utility of Circulating tumor DNA (ctDNA) as a biomarker for minimal residual disease (MRD) and depth of treatment response.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Other
Cancer type
Hodgkin Lymphoma
Disease stage
Required: Stage 2B, III, IV (Lugano)
Excluded: Stage I, IIA
Stage 2 B cHL with one or both of the following risk factors: Large mediastinal mass (≥1/3 of the maximum transverse thoracic diameter), Extranodal disease; Stage III or Stage IV cHL based on Lugano criteria
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: systemic lymphoma therapy (brentuximab vedotin)
Exception: Patients with prior treatment for indolent lymphoma are still eligible for participation as long as they did not receive anthracycline-based therapy.
Prior systemic lymphoma therapy including prior treatment with brentuximab vedotin. Note: Patients with prior treatment for indolent lymphoma are still eligible for participation as long as they did not receive anthracycline-based therapy.
Lab requirements
Blood counts
ANC >1,000 cells/mm3 (≥750 cells/mm3 if lymphoma involvement of the bone marrow or spleen); Platelets ≥75,000/mm3 (≥50,000/mm3 if lymphoma involvement of the bone marrow or spleen); Hemoglobin >9 g/dL (>8 g/dL in case of bone marrow involvement by lymphoma)
Kidney function
Creatinine within normal institutional limits or creatinine clearance ≥40 mL/min
Liver function
Serum total bilirubin ≤2x ULN (except patients with Gilberts syndrome); AST and ALT ≤2.5x institutional ULN (≤3x institutional ULN if lymphoma involvement of the liver)
Patients must have normal organ and marrow function as defined below: Absolute neutrophil count (ANC) >1,000 cells/mm3 independent of growth factor support within 7 days of study entry (≥750 cells/mm3 if lymphoma involvement of the bone marrow or spleen). Platelets ≥75,000 platelets/mm3 independent of transfusion support within 7 days of study entry (≥50,000 platelets/mm3 independent of transfusion support within 7 days of study entry if lymphoma involvement of the bone marrow or spleen). Hemoglobin >9 g/dL or >8 g/dL in case of bone marrow involvement by lymphoma independent of transfusion support within 7 days of study entry. Serum total bilirubin ≤2x upper limit of normal (ULN; except patients with Gilberts syndrome). Aspartate aminotransferase (AST; serum glutamic-oxaloacetic transaminase) and alanine transaminase (ALT; serum glutamic-pyruvic transaminase) ≤2.5x institutional ULN (≤3x institutional ULN if lymphoma involvement of the liver). Creatinine within normal institutional limits or creatinine clearance ≥40 mL/min (as estimated by the Cockcroft-Gault equation or alternative formula according to institutional guidelines) for patients with creatinine levels above institutional normal.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Miami · Miami, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07002216 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage 2B or III or IV is required.
Is there an age limit?
Yes. Patients must be 60 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages